4//SEC Filing
Craig Adam R 4
Accession 0000891293-23-000004
CIK 0000891293other
Filed
Jan 25, 7:00 PM ET
Accepted
Jan 26, 5:17 PM ET
Size
13.6 KB
Accession
0000891293-23-000004
Insider Transaction Report
Form 4
Craig Adam R
DirectorSee Remarks
Transactions
- Sale
common stock
2023-01-24$6.00/sh−83,200$499,200→ 29,440 total - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2023-01-24−83,200→ 472,171 totalExercise: $0.84Exp: 2029-05-16→ Common Stock (83,200 underlying) - Exercise/Conversion
common stock
2023-01-24$0.84/sh+2,117$1,781→ 31,557 total - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2023-01-24−2,117→ 470,054 totalExercise: $0.84Exp: 2029-05-16→ Common Stock (2,117 underlying) - Exercise/Conversion
common stock
2023-01-24$0.84/sh+83,200$69,980→ 112,640 total - Sale
common stock
2023-01-24$6.01/sh−2,117$12,723→ 29,440 total
Footnotes (2)
- [F1]This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person.
- [F2]One third of the shares underlying the option vested on 2/19/20 and annually thereafter until all the underlying shares were fully vested on 2/19/2022.
Documents
Issuer
CTI BIOPHARMA CORP
CIK 0000891293
Entity typeother
Related Parties
1- filerCIK 0001339498
Filing Metadata
- Form type
- 4
- Filed
- Jan 25, 7:00 PM ET
- Accepted
- Jan 26, 5:17 PM ET
- Size
- 13.6 KB